Please login to the form below

Not currently logged in
Email:
Password:

bone cancer

This page shows the latest bone cancer news and features for those working in and with pharma, biotech and healthcare.

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

Unsure on efficacy, NICE passes J&J’ s Darzalex to CDF. The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment. ... who have failed other drugs for the blood cancer, promoting J&J to ask for a review of fourth-line use.

Latest news

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    Roche gets FDA OKs for Alecensa and Zelboraf. Gains US licences for first-line use in lung cancer and a rare blood cancer. ... ECD is a slow-growing cancer that originates in the bone marrow and leads to excessive production of white blood cells know as

  • FDA fast-tracks Astellas' Rydapt rival FDA fast-tracks Astellas' Rydapt rival

    The FDA gave the status to gilteritinib as a treatment for adults with FLT3-mutation-positive relapsed or refractory acute myeloid leukaemia (AML), a cancer that impacts blood and bone marrow. ... According to the American Cancer Society, 21, 000

  • NICE finally set to back wider use of Ferring's Firmagon NICE finally set to back wider use of Ferring's Firmagon

    It follows a protracted appeals process over 2014 guidance that had limited use of the prostate cancer drug to a narrow patient population. ... can provide immediate reduction of cancer in the bone and stop this awful condition taking hold.

  • Imbruvica wins wider European leukaemia licence Imbruvica wins wider European leukaemia licence

    Despite Imbruvica's status as the most requested CLL drug available on the Cancer Drugs Fund (CDF), the cost-effectiveness watchdog claimed that it was not minded to approve an NHS ... A slow-progressing cancer of the bone marrow and blood cancer, CLL is

  • AbbVie and Roche to launch Venclexta within a week AbbVie and Roche to launch Venclexta within a week

    CLL is a slow-progressing cancer of the bone marrow and blood and is the most common leukaemia diagnosed in adults in western countries, with around 15, 000 new cases a ... The results showed that 80% of trial participants experienced a complete or

More from news
Approximately 2 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to

  • Case study: Treatment guidance Case study: Treatment guidance

    Challenge. Mifamurtide is a treatment for children, adolescents and young adults with a rare type of bone cancer, osteosarcoma.

  • Case study: Treatment guidance Case study: Treatment guidance

    Challenge. Mifamurtide is a treatment for children, adolescents and young adults with a rare type of bone cancer, osteosarcoma.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials. ... Additional revenues for these two drugs are also promised in other cancer types not to mention their “ combo” potential.

  • The distressing impact of rare diseases The distressing impact of rare diseases

    A US patient with Multiple Hereditary Exostosis (that can cause bone cancer) quoted in the report said: “ Finding a doctor that can treat me is the most difficult part.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics